Holen Sie sich die Stockscreener-App
1.86
3.33%
0.06
Handel nachbörslich:
1.86
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Digital Journal
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
Big Money Moves: Is NRx Pharmaceuticals Inc backed by strong institutional buying2026 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
NRx Pharmaceuticals Appoints Joshua C. Brown Chief Medical Innovation Officer - MyChesCo
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment - Digital Journal
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD - The Manila Times
NRx Pharmaceuticals (NRXP) to Release Earnings on Friday - MarketBeat
HC Wainwright Has Positive Estimate for NRXP FY2026 Earnings - MarketBeat
What are NRx Pharmaceuticals Inc. Equity Warrant’s growth leversQuarterly Portfolio Summary & Low Risk Entry Point Guides - mfd.ru
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 By Investing.com - Investing.com India
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com Nigeria
Q3 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst - MarketBeat
NRXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00 - MarketBeat
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer - Investing.com
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer - Digital Journal
NRx Pharmaceuticals (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway - Digital Journal
NRx Pharmaceuticals Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Investing News Network
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer By Investing.com - Investing.com Canada
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer - marketscreener.com
What is the dividend yield of NRx Pharmaceuticals IncMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
NRx Builds Momentum From FDA Progress To Strategic Expansion - National Today
NRx Builds Momentum From FDA Progress To Strategic Expansion | Corporate - EQS News
NRXP Technical Analysis & Stock Price Forecast - Intellectia AI
EQS-News: Benzinga: NRx Builds Momentum From FDA Progress To Strategic Expansion - FinanzNachrichten.de
NRXP Should I Buy - Intellectia AI
NRXPW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Reports FDA Guidance on NRX-100 Approval Path - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bipolar Depression Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider
Trade Report: Can NRx Pharmaceuticals Inc stock outperform in a bear market2025 Trading Recap & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Weekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020 - finanzen.ch
Moving Averages: What is the earnings history of Guidewire Software Inc2025 Technical Overview & Expert Approved Momentum Ideas - baoquankhu1.vn
Ideas Watch: Is NRx Pharmaceuticals Inc backed by strong institutional buyingQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
NRx and FDA Meeting Advances New Drug Application for NRX-100 - Intellectia AI
NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at BTIG Research - Defense World
BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - The Globe and Mail
NRx Pharmaceuticals Announces Path to New Drug Application - citybiz
FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - StreetInsider
FinancialContentFDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - FinancialContent
NRx Pharmaceuticals Establishes $20 Million ATM Stock Program - TipRanks
[8-K] NRX Pharmaceuticals, Inc. Reports Material Event | NRXP SEC FilingForm 8-K - Stock Titan
NRx Pharmaceuticals Charts Path To NDA For NRX-100 Following FDA Guidance - Nasdaq
FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP - PRLog
NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at D. Boral Capital - MarketBeat
Nrx Pharmaceuticals announces path to new drug application with real world data - marketscreener.com
NRx Pharmaceuticals Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 Following Type C FDA Meeting - Investing News Network
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application With Real World Data and Broader Proposed Indication for NRX-100 (Ketamine) Following Type C FDA Meeting - 富途牛牛
What is NRx Pharmaceuticals Inc.’s book value per share2025 Price Targets & Low Risk High Reward Trade Ideas - mfd.ru
CEO Change: What is the Moat Score of IGC Pharma IncProduct Launch & Weekly High Momentum Picks - baoquankhu1.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Decrease in Short Interest - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):